Accel and Prosus Are Quietly Rewriting the Deep‑Tech Playbook in India

India’s startup story has mostly been told through food delivery, fintech and cheap data. This new cohort from Accel and Prosus points in a very different direction: reusable rockets, brain–computer interfaces and dogs sniffing out cancer. If it works, it won’t just change India’s tech narrative; it could redraw where the world goes hunting for deep‑tech breakthroughs. In this piece, we’ll unpack what Accel and Prosus are really doing, why this model matters far beyond India, and what European founders and investors should be paying attention to.

The news in brief

According to TechCrunch, Accel and Prosus have picked six startups for the first India cohort of their joint program focused on what they call “off‑the‑map” ideas – companies operating in areas where markets are fuzzy and traditional growth metrics don’t apply.

From more than 2,000 applications, they selected:

• Praan, building indoor air infrastructure systems that combine purification, sensing and automation.
• QOSMIC, developing optical communication links between satellites and Earth to boost bandwidth and cut latency.
• Ethereal Exploration Guild (EtherealX), working on reusable orbital launch vehicles.
• Dognosis, using dogs’ sense of smell, robotics and AI to detect cancers from breath samples.
• Ferra, a home strength‑training system designed to preserve mobility in ageing populations.
• A stealth‑mode startup developing brain–computer interfaces (BCI).

As reported by TechCrunch, Accel and Prosus are co‑investing cheques between $500,000 and $2 million in each company. Prosus matches Accel’s capital, and part of the investment is structured to delay some dilution for founders – a nod to the long, non‑linear development cycles typical of deep‑tech.

Why this matters

The most important thing here is not which six startups made the cut, but what this says about where top‑tier capital believes the next decade of value will be created.

Accel built its India franchise on consumer internet and SaaS. Prosus is globally known for bets like Tencent and its food‑delivery portfolio. For these two to explicitly hunt for “undefined markets” in India is a signal: the easy arbitrage of copying Western consumer apps is mostly done. The next frontier is hard science plus hard engineering.

Winners in this shift:

• Deep‑tech founders who previously struggled to raise outside government grants or niche funds. Their problems (BCI, launch vehicles, non‑invasive cancer detection) don’t fit the GMV‑and‑CAC spreadsheet that dominated the last cycle.
• Long‑horizon LPs who missed the last Indian consumer wave. Deep‑tech is late, but not too late: the big value creation is still ahead if patience is available.

Potential losers:

• Quick‑flip venture funds optimised for 3–5 year exits. These startups may need a decade before meaningful revenue.
• Copy‑paste founders; there is little room for “India’s Uber for X” in this cohort.

The funding structure is just as important as the sector focus. By deferring part of the equity give‑up, Accel and Prosus are acknowledging a basic truth of deep‑tech: if you force founders to sell too much too early, you kill the incentive for them to grind through years of R&D before commercial traction.

The bigger picture

Globally, this move sits inside a broader re‑rating of deep‑tech.

In the US, the last few years saw increasing venture interest in space (SpaceX, Rocket Lab, Relativity), longevity (Altos Labs, Retro) and BCI (Neuralink, Synchron). Europe has its own wave: ispace Europe, Isar Aerospace, ICEYE, Quantum‑Systems and a growing list of quantum and photonics startups backed by funds like IQM‑linked investors, EQT, and the EIC Accelerator.

India has been late to that party, but the context is changing fast:

• Space: ISRO’s cost‑efficient missions have proven the depth of local engineering talent. Private players like Skyroot and Agnikul already showed that launch vehicles are not a Western monopoly.
• Climate and air quality: cities like Delhi and Mumbai are living laboratories for air‑pollution tech. A company like Praan has a brutally clear local problem and a global market.
• Healthcare and ageing: while India is still demographically young, it will age quickly; at the same time, Western healthcare systems are desperate for cheaper diagnostics and preventative tools. A Dognosis that actually works is a global product from day one.

The other macro‑trend is experimentation with funding instruments. Around the world we see revenue‑based financing, venture debt, “venture studios” and catalytic public funding. Accel and Prosus are adding another variant: staged ownership designed for non‑linear progress. Instead of punishing startups for spending three years in a lab, they are effectively time‑shifting part of the dilution to when the risk is lower and the company is more valuable.

This is much closer to how biotech and hardware have been financed historically than to the blitzscaling playbooks of the 2010s. The fact that a mainstream India‑focused program adopts this model suggests deep‑tech is moving from edge case to first‑class citizen in the venture asset class.

The European / regional angle

For European readers, the instinctive reaction might be: interesting, but far away. That’s the wrong lens.

Europe has world‑class research, strong industrial bases in space, automotive, healthcare and photonics, and increasingly sophisticated public tools (Horizon Europe, EIC, national deep‑tech funds). What we often lack is cost‑efficient, risk‑tolerant implementation at scale. India is building exactly that.

These six startups sit at natural Europe–India junctions:

• Space and optical communications: European players like OHB, Airbus Defence & Space and a host of NewSpace startups are building constellations and downstream services. A QOSMIC‑type company could become a supplier, partner or competitor.
• BCI and medical AI: once you involve brain data or diagnostic algorithms, you immediately run into GDPR, the Medical Device Regulation and, soon, the EU AI Act. Any India‑built health or BCI product sold into Europe will be shaped by those rules.
• Longevity and ageing: Ferra’s focus on home strength‑training hits a European mega‑trend: rapidly ageing populations and strained social‑care systems, particularly in countries like Germany, Italy and Spain.

For European VCs, this cohort is also a reminder that dealflow is now genuinely global at the pre‑product stage. You may meet an Indian BCI founder at Web Summit or Slush long before they have any EU presence. Understanding how their cap tables and risk profiles were shaped by programs like this will matter when you consider a Series A or B.

Looking ahead

What happens next will determine whether this program becomes a curiosity or a template.

In the next 12–24 months, don’t expect these startups to look like typical venture successes. The key milestones won’t be revenue curves; they will be:

• demonstration flights for EtherealX,
• stable high‑throughput optical links for QOSMIC,
• validated clinical studies for Dognosis,
• regulatory pathways and safety for the BCI company,
• repeatable user outcomes for Ferra and Praan.

If even two or three of the six can hit credible technical milestones and raise meaningful follow‑on rounds, Accel and Prosus will have proven that India can incubate globally relevant deep‑tech without relying solely on Western accelerators or government labs.

Risks are obvious. Global capital markets could tighten further, making follow‑on funding brutal for anything without short‑term revenue. Regulatory shocks – particularly around AI in healthcare and neurotech – could slow down or fragment markets. And there is always execution risk: rockets blow up, dogs misclassify samples, BCIs fail to generalise beyond tiny patient cohorts.

The opportunity, however, is asymmetric. If a single company from this cohort becomes the SpaceX‑equivalent for low‑cost launches, or a globally trusted early‑stage cancer screen, the entire risk pool is paid back many times over.

For readers on the investing side, the signal to watch is not headlines but who shows up in the next round. When you see specialised funds from the US, Europe or Japan co‑leading Series A and B deals for this cohort, you will know the experiment is working.

The bottom line

Accel and Prosus are using India as a laboratory for a different kind of venture: slower, riskier, but aimed at genuinely frontier problems. That should matter to anyone who cares about where the next generation of space, climate and health breakthroughs will come from. The open question is whether founders, LPs and regulators are prepared to live with a decade of uncertainty in exchange for outsized impact. Are we finally ready to fund science with the same enthusiasm we funded food delivery?